Aclaris Therapeutics ACRS Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies
Other financials
Where this comes from
Reported directly by Aclaris Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.
The official record: Aclaris Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aclaris Therapeutics's comprehensive income (loss), net of tax, attributable to parent.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aclaris Therapeutics's comprehensive income (loss), net of tax, attributable to parent?
- Aclaris Therapeutics (ACRS) reported comprehensive income (loss), net of tax, attributable to parent of -$20.41M in Q1 2026.
- How has Aclaris Therapeutics's comprehensive income (loss), net of tax, attributable to parent changed year-over-year?
- Aclaris Therapeutics's comprehensive income (loss), net of tax, attributable to parent decreased by 38.4% year-over-year, from -$14.75M to -$20.41M.
- What is the long-term trend for Aclaris Therapeutics's comprehensive income (loss), net of tax, attributable to parent?
- Over 4 years (2021 to 2025), Aclaris Therapeutics's comprehensive income (loss), net of tax, attributable to parent has grown at a -8.3% compound annual growth rate (CAGR), from -$91M to -$64.41M.
- What does comprehensive income (loss), net of tax, attributable to parent mean?
- Represents the total change in the company's net assets from non-owner sources, combining net income with other comprehensive income items. This figure provides a comprehensive view of the company's total financial health and the impact of both operational performance and external market factors. Investors use this to understand the full scope of changes in the company's equity position over the reporting period.